Bone Morphogenetic Protien

Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee

NEW YORK, Oct. 19, 2015 /PRNewswire/ — Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis,…